

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-37. (Canceled)

38. (Currently amended) An immunogenic composition comprising an immunologically effective amount of a purified polypeptide comprising the amino acid sequence of SEQ ID NO:3, or a purified, recombinant polypeptide fragment of the amino acid sequence of SEQ ID NO:3, which polypeptide or said polypeptide fragment: (i) is immunologically identifiable by an antibody that reacts specifically with *H. pylori* cytotoxin and (ii) exhibits no cytotoxic activity or reduced cytotoxic activity compared with *Helicobacter pylori* cytotoxin purified from cell cultures.

39-43. (Canceled)

44. (Currently amended) An immunogenic composition comprising an immunologically effective amount of a purified, recombinantly produced polypeptide comprising the amino acid sequence of SEQ ID NO:3, or a purified, recombinant polypeptide fragment of the amino acid sequence of SEQ ID NO:3, wherein said recombinantly produced polypeptide or said polypeptide fragment (i) is immunologically identifiable by an antibody that reacts specifically with *H. pylori* cytotoxin and (ii) exhibits no cytotoxic activity or reduced cytotoxic activity compared with *Helicobacter pylori* cytotoxin purified from cell cultures, and a pharmaceutically acceptable carrier.

45. (Currently amended) An immunogenic composition comprising an immunologically effective amount of a purified polypeptide comprising the amino acid sequence of SEQ ID NO:3, or a purified recombinant polypeptide fragment of the amino acid sequence of SEQ ID NO:3, which polypeptide or said fragment: (i) is immunologically identifiable by an antibody that reacts specifically with *H. pylori* cytotoxin and (ii) exhibits

DOCKET NO.: CHIR-0315
Application No.: 09/921,157
Office Action Dated: November 3, 2004

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

no cytotoxic activity or reduced cytotoxic activity compared with *Helicobacter pylori* cytotoxin purified from cell cultures, and a pharmaceutically acceptable carrier.

46. (Currently amended) An immunogenic composition comprising an immunologically effective amount of a purified, recombinantly produced polypeptide comprising the amino acid sequence of SEQ ID NO:3, or a purified, recombinant polypeptide fragment of the amino acid sequence of SEQ ID NO:3, wherein said recombinantly produced polypeptide or said polypeptide fragment (i) is immunologically identifiable by an antibody that reacts specifically with *H. pylori* cytotoxin and (ii) exhibits no cytotoxic activity or reduced cytotoxic activity compared with *Helicobacter pylori* cytotoxin purified from cell cultures.